Saturday, October 1, 2022
Mitochondrial Health

March 30, 2022 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee



The committee will discuss new drug application (NDA) 216660, for sodium phenylbutyrate/taurursodiol (AMX0035) powder for oral suspension, submitted by Amylyx Pharmaceuticals Inc., for the treatment of amyotrophic lateral sclerosis (ALS).

source

Similar Posts

Leave a Reply

Your email address will not be published.